Top Markets
#1 Black Phoenix Black Phoenix +828.22%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.74%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +25.29%
#4 Bless Bless +21.01%
#5 SAFEcoin SAFEcoin +20.57%
#6 pipedog pipedog +20.53%
#7 Magma Finance Magma Finance +20.34%
#8 PondCoin PondCoin +20.03%
#9 Beam Beam +19.60%
#10 YFSX YFSX +16.01%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CymaBay Therapeutics, Inc. CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc.

CBAY
Classifica tra le azioni #6078
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Prezzo delle azioni
$32.48
Ultima sincronizzazione: 2024-03-25
Capitalizzazione di mercato
$2.24B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia CymaBay Therapeutics, Inc. (CBAY)

Categoria

Healthcare
EPS per CymaBay Therapeutics, Inc. (CBAY)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di CymaBay Therapeutics, Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per CymaBay Therapeutics, Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH